Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
21.24 USD | +1.21% | -1.71% | -11.55% |
05-14 | Stephens Initiates Exelixis With Equalweight Rating, $23 Price Target | MT |
05-10 | Exelixis Files Patent Complaint Against Cipla's Cancer Treatment | DJ |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-11.55% | 6.11B | |
+6.01% | 111B | |
+11.67% | 106B | |
-12.42% | 22.24B | |
+0.38% | 21.25B | |
-5.01% | 18.97B | |
-35.21% | 18.52B | |
-11.45% | 16.81B | |
+38.17% | 12.54B | |
-24.96% | 8.09B |
- Stock Market
- Equities
- EXEL Stock
- News Exelixis, Inc.
- JMP Securities Adjusts Price Target on Exelixis to $25 From $26, Maintains Market Outperform Rating